A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine TumorsSandip Pravin Patel, Razelle Kurzrock, Christine M. McLeod et al.|Clinical Cancer Research|2020Cited by 326
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†J. Alfred Witjes, Donna E. Hansel, Marek Babjuk et al.|European Urology|2019Cited by 191
EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines CommitteesAlan Horwich, Donna E. Hansel, Marek Babjuk et al.|Annals of Oncology|2019Cited by 182
Mammalian Target of Rapamycin (mTOR) Regulates Cellular Proliferation and Tumor Growth in Urothelial CarcinomaDonna E. Hansel, Charis Eng|American Journal Of Pathology|2010Cited by 79
Metabolomics analysis reveals distinct profiles of nonmuscle‐invasive and muscle‐invasive bladder cancerDivya Sahu, Donna E. Hansel|Cancer Medicine|2017Cited by 74